reports
Declaration of voting rights - Valneva SE, March 2024
Declaration of voting rights - Valneva SE, March 2024 VALNEVA Declaration of shares and voting rights March 31, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: April 4, 2024 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of voting right...
Déclaration d'actions et de droits de vote de la société Valneva SE - ...
Déclaration d'actions et de droits de vote de la société Valneva SE - mars 2024 VALNEVA Déclaration d’actions et de droits de vote 31 mars 2024__________________________________________________________________________________________ Dénomination sociale : VALNEVAAdresse du siège social : 6 rue Alain Bombard, 44800 Saint-HerblainMarché réglementé Euronext Paris - Compartiment B Date de la déclaration : 4 avril 2024 Nombre d’actions composant le capital de Valneva Nombre total de droits de vote incluant les droi...
- Pierre Dinet (IDMidCaps)
Trigano - A company clearly undervalued after uncertainties over 2023/...
Trigano reported Q2 sales well above our expectations (+16% vs. +10% organic), driven by motorhomes despite a very high base effect.The Group is very positive both on the level of annual organic growth (+10% confirmed) and on profitability, with an improvement in EBIT Margin expected.With regard to Bio-Habitat, an initial response from the French Competition Authority is expected in June, but there is considerable uncertainty as to the outcome.We are back to Buy with a price target raised to €18...
- Andreas Riemann
- Jean Danjou
- Usama Tariq
ODDO BHF Small & MIDCAP MORNING NEWS - 03/28/2024
With the exception of the US, construction markets should continue to shrink in 2024 (-2% in Europe) before rebounding on the back of lower interest rates. Against this backdrop, groups will be differentiated mainly on the basis of their resilience (geographical and price/cost mix), capital allocation (and special situations) and valuation. In this context, we are upgrading our recommendations on KONE (modernisation as an alternative source of growth to China) and Holcim (a substantia...
OSE OSE IMMUNOTHERAPEUTICS SA
ZIL2 ELRINGKLINGER AG
SBS STRATEC SE
F3C SFC ENERGY AG
HCO HIGHCO SA
CGM CEGEDIM SA
VRAP VRANKEN-POMMERY MONOPOLE SA
LNA LNA SANTE SA
TRI TRIGANO SA
BCP BANCO COMERCIAL PORTUGUES S.A.
QDT QUADIENT SA
SESL SES-IMAGOTAG SA
BEZ BERENTZEN GRUPPE
ALBFR SIDETRADE SA
SMHN SUESS MICROTEC AG
JUN3 JUNGHEINRICH AG PREF
S92 SMA SOLAR TECHNOLOGY AG
RBO ROCHE BOBOIS INTERNATIONAL SAS
JEN JENOPTIK AG
KTA KNAUS TABBERT
INPST INPOST S.A.
MRX MISTER SPEX SE
LHYFE LHYFE S.A.
- Andreas Riemann
- Jean Danjou
- Usama Tariq
ODDO BHF Small & MIDCAP MORNING NEWS - 28/03/2024
Hormis les Etats-Unis, les marchés de la construction devraient continuer à reculer en 2024 (-2% en Europe) avant de rebondir à la faveur d’une baisse des taux. Dans ce contexte, la différenciation entre les groupes se fera essentiellement sur leur capacité de résistance (mix géographique et prix/ coûts), l’allocation du capital (et situations spéciales) et leur valorisation. Face à cet environnement, nous relevons nos recommandations sur KONE (la modernisation comme relais de la Chin...
OSE OSE IMMUNOTHERAPEUTICS SA
ZIL2 ELRINGKLINGER AG
SBS STRATEC SE
TNG TRANSGENE SA
F3C SFC ENERGY AG
HCO HIGHCO SA
CGM CEGEDIM SA
NTG NETGEM SA
VRAP VRANKEN-POMMERY MONOPOLE SA
LNA LNA SANTE SA
TRI TRIGANO SA
BCP BANCO COMERCIAL PORTUGUES S.A.
QDT QUADIENT SA
SESL SES-IMAGOTAG SA
BEZ BERENTZEN GRUPPE
ALBFR SIDETRADE SA
SMHN SUESS MICROTEC AG
JUN3 JUNGHEINRICH AG PREF
S92 SMA SOLAR TECHNOLOGY AG
RBO ROCHE BOBOIS INTERNATIONAL SAS
JEN JENOPTIK AG
KTA KNAUS TABBERT
INPST INPOST S.A.
MRX MISTER SPEX SE
LHYFE LHYFE S.A.
- Christophe Chaput
Trigano : Excellent H1 sales with a reassuring message on trends in pr...
>Excellent H1 sales: € 1,905.8m vs € 1,828.1m est. - Trigano reported excellent H1 2023-24 sales figures. Sales were up 18.4% to € 1 905.8m whereas we looked for € 1,828.1m (gap +4.3%). At constant scope and currencies, growth was 17.2%. For Q2, organic growth was therefore +15.9% (+16.8% for leisure vehicles), which is an excellent performance, with a base of comparison in Q2 that was less favourable than that in Q1. As a reminder, l-f-l growth in Q1 2024 was 18.7% v...
- Christophe Chaput
Trigano : Excellent CA S1 avec un message rassurant sur l’évolution de...
>Un excellent CA S1 : 1 905.8 M€ vs 1 828.1 M€ estimé - Au titre de son premier semestre, le groupe Trigano publie un excellent chiffre d’affaires. Celui-ci progresse de 18.4% à 1 905.8 M€ alors que nous retenions 1 828.1 M€ (écart +4.3%). A périmètre et change constants, la hausse est de 17.2%. Pour le seul T2, la croissance organique est donc de +15.9% (+16.8% pour les Véhicules de Loisirs) ce qui est une excellente performance, avec une base de comparaison sur le T...
- Oscar Haffen Lamm
VALNEVA: Initiates phase 1 trial of the Zika vaccine candidate
Valneva announced the initiation of the phase 1 trial of the Zika vaccine candidate (VLA1601), its 2nd generation adjuvanted inactivated vaccine, which will investigate its safety and immunogenicity. The phase 1 will enroll approx. 150 participants (18-49 years old) in the US who will receive a low
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Cand...
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate Saint-Herblain (France), March 26, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV). There are currently no preventive vaccines or effective treatments available against ZIKV. As such, this mosquito-borne disease remains a public health threat and is included in the Food and Dru...
Valneva lance un essai de Phase 1 sur son candidat vaccin de deuxième ...
Valneva lance un essai de Phase 1 sur son candidat vaccin de deuxième génération contre le virus Zika Saint-Herblain (France), le 26 mars 2024 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui l’initiation d’un essai de Phase 1 pour évaluer l’innocuité et l’immunogénicité de VLA1601, son candidat vaccin inactivé et adjuvanté de deuxième génération contre le virus Zika (ZIKV). Il n'existe pas de vaccins préventifs ni de traitements efficaces contre le virus Zika qui demeure donc une menace pour la santé publique et a été inclus dans le pro...
Valneva Announces Filing of 2023 Universal Registration Document and U...
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F Saint-Herblain (France), March 25, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.24-0157 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC). Valneva’s 2023 Universal Registration Document – available in its entirety in French – includes the Company’s 2023 Annual Financial Report, the Compan...
Valneva annonce le dépôt de son Document d’Enregistrement Universel 20...
Valneva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son rapport annuel américain « Form 20-F » Saint-Herblain (France), 25 mars 2024 – (Nasdaq : VALN; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui le dépôt, le 22 mars 2024, de son Document d’enregistrement universel 2023 auprès de l’Autorité des Marchés Financiers (AMF) sous le numéro D.24-0157, et de son rapport annuel « Form 20-F » auprès de la Securities and Exchange Commission (SEC) aux Etats-Unis. Le Document d’enregistrement universel 2023 de Valneva – disponible dans s...
- Oscar Haffen Lamm
Valneva: Model Update
Post-FY23 earnings publication on the 20th March, we have updated our model with an unchanged BUY rating and PT at EUR 9. We adjusted our estimates for product sales taking into account the upgraded guidance for 2024 and the mid-term outlook provided by the company, namely i) Ixiaro guided continue
Valneva fera une présentation sur son vaccin contre le chikungunya, IX...
Valneva fera une présentation sur son vaccin contre le chikungunya, IXCHIQ®, et participera à plusieurs événements lors du 24ème World Vaccine Congress à Washington, D.C. Saint-Herblain (France), le 21 mars 2024 – (Nasdaq : VALN; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui qu’elle fera une présentation sur son vaccin à injection unique contre le chikungunya, IXCHIQ®, animera une table ronde sur les virus Zika et chikungunya, et participera à un débat sur les efforts d'éradication du chikungunya lors du 24ème World Vaccine Congress, qui se tiendra du 1...
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in ...
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C. Saint-Herblain (France), March 21, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it will present on its single-shot chikungunya vaccine, IXCHIQ®, moderate a roundtable on the Zika and chikungunya viruses, and participate in a panel discussion on efforts to eradicate chikungunya at the 24th World Vaccine Congress, which will take place between April 1-4, 2024 at the Walter E. Washington convention center in Was...
- Fehmi Ben Naamane
- Thomas Zlowodzki
ODDO BHF Small & MIDCAP MORNING NEWS - 03/20/2024
We are upgrading the energy sector to Overweight vs Neutral (excluding Oil Services, already on Overweight). The recent rebound in oil prices is set to continue, driven by short, medium and long-term factors: value, cyclical, little debt and good shareholder returns. Technical analysis reveals a strong trend that is only just beginning. GALP enters our Large Caps list; CellNex exits it. - ...
WTB WHITBREAD PLC
EURN EURONAV NV
CEN GROUPE CRIT SA
BEN BENETEAU SA
VIRP VIRBAC SA
VLS VALNEVA SE
PIG HAULOTTE GROUP SA
ISP INTESA SANPAOLO S.P.A.
DEQ DEUTSCHE EUROSHOP AG
SBO SCHOELLER-BLECKMANN OILFIELD EQUIPMENT AG
ALVIV VISIATIV SA
UCG UNICREDIT S.P.A.
SHOT SCANDIC HOTELS GROUP
MEL MELIA HOTELS INTERNATIONAL S.A.
NHH NH HOTEL GROUP SA
COPN COSMO PHARMACEUTICALS NV
PWG PRODWAYS GROUP SA
IHG INTERCONTINENTAL HOTELS GROUP PLC
CABKA CABKA N.V.
- Damien Choplain
- Martial Descoutures
Valneva : Announcement of an attractive medium-term outlook
>Adjusted EBITDA better than expected - Adjusted EBITDA came to -€ 65m, above the consensus at -€ 72m. We retain: 1/ total sales (already reported) down 57% y-o-y at € 154m, impacted by an unfavourable base effect as 2022 included € 280m in revenues related to the Covid vaccine supply agreement (product sales are up 26% and 63% excluding Covid vaccines); 2/ a total gross margin for product sales stable at 46% vs 45.5% in 2022, but down for Ixiaro (52% vs 62% in 2022)...
- Fehmi Ben Naamane
- Thomas Zlowodzki
ODDO BHF Small & MIDCAP MORNING NEWS - 20/03/2024
Nous upgradons le secteur énergie à Surpondérer vs Neutre (hors Oil Services déjà à Surpondérer). Le rebond récent des prix du pétrole va se poursuivre, soutenu par des facteurs à court, moyen et long terme. Le secteur dispose en outre de 4 atouts dans la configuration de marché actuelle : value, cyclique, peu endetté et bon retour à l’actionnaire. L’analyse technique révèle une tendance forte qui ne fait que commencer. GALP fait son entrée dans notre liste Large Caps ; CellNex en so...
WTB WHITBREAD PLC
EURN EURONAV NV
CEN GROUPE CRIT SA
BEN BENETEAU SA
VIRP VIRBAC SA
VLS VALNEVA SE
PIG HAULOTTE GROUP SA
ISP INTESA SANPAOLO S.P.A.
DEQ DEUTSCHE EUROSHOP AG
SBO SCHOELLER-BLECKMANN OILFIELD EQUIPMENT AG
ALVIV VISIATIV SA
UCG UNICREDIT S.P.A.
SHOT SCANDIC HOTELS GROUP
MEL MELIA HOTELS INTERNATIONAL S.A.
NHH NH HOTEL GROUP SA
COPN COSMO PHARMACEUTICALS NV
PWG PRODWAYS GROUP SA
IHG INTERCONTINENTAL HOTELS GROUP PLC
CABKA CABKA N.V.
- Oscar Haffen Lamm
VALNEVA: Upgraded FY 2024 guidance
Valneva reported its FY 2023 revenues and provided an upgraded revenue guidance for 2024. As preliminary results have already been reported for its revenues no surprises were reported on that end with revenues confirmed at EUR 153.7m, of which product sales EUR 144.6m. Strong growth in all product
- Damien Choplain
- Martial Descoutures
Valneva : Annonce de perspectives MT attractives
>EBITDA ajusté meilleur qu’attendu - L’EBITDA ajusté ressort à -65 M€, au-dessus du Css à -72 M€. Nous retenons 1/ un CA total (déjà publié) en baisse de 57% YoY à 154 M€ impacté par un effet de base défavorable puisque 2022 comprenait 280 M€ de revenus liés aux accords de fourniture de vaccins COVID-19 (les ventes de produits sont en hausse de 26% et 63% hors vaccins COVID) , 2/ une marge brute totale sur les ventes de produit stable à 46% vs 45.5% en 2022, mais en ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.